Author Index—2002

Note: (ab) represents abstract

A

Abi-Dargham, A, 1556(ab)
Afriyie, MO, 1568(ab), 1573(ab)
Allidina, Y, 1628(ab)
Alvarez, R, 1580(ab)
Anger, RT, 1624(ab)
Anstett, F, 1564(ab)
Arroyo, AJ, 1604(ab)
Assaei, R, 1602(ab)

B

Bacetti, N, 1559(ab)
Ballow, J, 21
Barrow, SA, 1609(ab)
Bartlett, ML, 25
Beyder, D, 1629(ab)
Bhargava, KK, 1573(ab)
Bodenstein, C, 1574(ab)
Bodey, RK, 1606(ab)
Bohnen, N, 1611(ab), 1612(ab)
Bohuslavizki, KH, 185
Bonab, AA, 1609(ab)
Bondarenko, A, 1623(ab)
Borges-Neto, S, 175
Bridwell, RS, 1564(ab)
Brinkbaeumer, K, 1608(ab)
Bull, MP, 1626(ab)
Burch, A, 1606(ab)
Burkhalter, W, 179
Burroughs, MR, 31
Buscombe, JR, 1578(ab)

C

Cangiano, C, 1556(ab)
Carey, AM, 1552(ab)
Carr, B, 1611(ab), 1612(ab)
Cerfolio, RJ, 1575(ab)
Chen, JC, 1567(ab)
Cheng, KT, 1616(ab)
Chyou, PH, 1627(ab)
Clark, PA, 1577(ab)
Clarke, D, 1606(ab)
Clarke, M, 2, 38
Clausen, M, 185
Clements, IP, 1558(ab)
Coleman, RE, 175
Collins, AM, 1551(ab)
Collins, L, 1612(ab)
Collins, LL, 1611(ab), 1614(ab)
Cone, L, 1554(ab)
Connolly, LC, 1613(ab)
Corbilla, R, 1561(ab)
Corcoran, TE, 1614(ab)
Corstens, FH, 1576(ab)
Crawford, ES, 18, 165
Cuklanz, EJ, 59, 134, 192

D

Daftary, A, 1615(ab)
D'Agnolo, A, 1561(ab)
Davis, RT, 1613(ab)
Dawadi, BR, 53
Dawardi, B, 194
Derango, A, 1603(ab)
Di Carli, MF, 1560(ab)
Dickson, JC, 1578(ab)
Dilsizian, V, 1559(ab)
Ditt, H, 1605(ab)
Dorbala, S, 1560(ab)
Dresel, S, 1608(ab)
Durbin, AL, 1626(ab)

E

Elias, G, 1604(ab)
Elliott, G, 1580(ab)
Emmett, L, 1601(ab)
Erwin, WD, 1603(ab)
Evans, WD, 1606(ab)

F

Fahey, FH, 39
Fairbank, C, 1556(ab)
Farago, P, 1560(ab)
Fischman, AJ, 1609(ab)
Fisher, RS, 1554(ab)
Folks, R, 1572(ab)
Folks, RD, 153
Fong, C, 1628(ab)
Frater, C, 1601(ab)
Fujita, K, 1557(ab)
Fukunaga, I, 1570(ab)

G

Gebert, KM, 1621(ab)
Gee-Johnson, S, 12
Gerbaudo, VH, 1560(ab)
Geworski, L, 1605(ab)
Gil, R, 1556(ab)
Gordon, L, 179
Gorman, JM, 1556(ab)
Grady, J, 1603(ab)
Grahneis, J, 1565(ab)
Grancorvitz, AS, 1622(ab)
Gray, PJ, 25
Gregory, MJ, 1615(ab)
Groch, MW, 1603(ab)
Groch, PJ, 1603(ab)
Guo, J, 1554(ab)

H

Hachamovitch, R, 1560(ab)
Hackett, E, 1556(ab)
Hahn, K, 1608(ab)
Halama, J, 1563(ab)
Hamacher, KA, 1551(ab)
Hanson, MW, 175
Harkness, B, 1, 37, 107, 151
Harris, MS, 1623(ab)
Heath, G, 1578(ab)
Heidary, A, 1602(ab)
Hilson, AJ, 1578(ab)
Hovey, S, 18
Hyun, M, 1561(ab)

I

Iacono, AT, 1614(ab)
Ichise, M, 1555(ab)
Innis, RB, 1555(ab)
Ivancevic, V, 1605(ab)

J

Jenkins, JJ, 1553(ab)
Jessop, M, 1578(ab)
Johnson, B, 36, 61
Johnston, C, 61
Jordan, J, 149
Josephs, P, 1578(ab)

K

Kalaparambath, T, 1568(ab)
Kalman, S, 63(le)
Kamuf, AC, 1624(ab)
Kantor, SB, 1554(ab)
Kao, T, 1571(ab)
Kasner, DL, 128
Keech, F, 152
Keech, FK, 108
Kelly, SJ, 1560(ab)
Kennedy, A, 1553(ab)
Khazaeli, M, 1580(ab)
Kim, EE, 12
Klutmann, S, 185
Knight, A, 33, 131
Knight, AW, 190, 194
Knight, LC, 1554(ab)
Knudsen, GM, 1610(ab)
Kochan, LD, 1556(ab)
Kochan, P, 1554(ab)
Kok, PJ, 1576(ab)
Kourmouzi, VC, 1613(ab)

L

Lang, RE, 1621(ab)
Laruelle, M, 1556(ab)
Leal, JP, 1569(ab)
Legreve, SB, 1622(ab)
Leveque, F, 1568(ab), 1573(ab)
Li, T, 1607(ab)
Li, X, 1607(ab)
Liang, J, 1607(ab)
Liddle, SJ, 1630(ab)
Line, BR, 1553(ab), 1559(ab)
Liow, J, 1555(ab)
Liu, H, 1575(ab)
Liu, RS, 1567(ab), 1571(ab)
Lodge, M, 1559(ab)
Lodge, MA, 1553(ab)
Lorusso, A, 1560(ab)
Lundberg, TM, 25
Luqman, M, 1562(ab)

M

Maass-Moreno, R, 1555(ab)
Madras, BK, 1609(ab)
Magram, M, 1559(ab)
Mah, E, 179
Mahone, TJ, 1575(ab)
Mann, A, 130, 189
Mansel, RE, 1606(ab)
Mar, MV, 12
Marshall, LT, 1569(ab)
Masoomi, MA, 1562(ab)
Maurer, AH, 1554(ab)
Mawlawi, O, 1556(ab)
Maza, S, 1605(ab)
McCook, B, 1611(ab), 1612(ab)
McCook, BM, 1614(ab)
McCrum, A, 1563(ab)
Meredith, R, 1580(ab)
Meyers, AM, 21
Minutello, R, 1551(ab)
Mirkovic, N, 1563(ab)

Montilla, JS, 1564(ab)
Morgan, M, 1623(ab)
Mountz, JM, 1575(ab)
Muehler, M, 1605(ab)
Mukherjee, S, 1575(ab)
Mullan, BP, 1558(ab)
Müller, V, 185
Munz, DL, 1605(ab)
Murtha, P, 1614(ab)
Murthy, R, 1553(ab)

N

Nabi, HA, 3
Nakamoto, N, 1577(ab)
Nakamura, T, 1557(ab)
Ng, WS, 1630(ab)
Nomura, N, 1557(ab)

O

Ojha, BC, 1575(ab)
Okamoto, N, 1557(ab)
Owens, TP, 1558(ab)
Oyen, WJ, 1576(ab)
Ozaki, Y, 1570(ab)

P

Pagnanelli, RA, 175
Palestro, CJ, 1568(ab), 1573(ab)
Palmer, M, 1562(ab)
Panganamamula, KV, 1554(ab)
Parkman, HP, 1554(ab)
Parthasarathy, KL, 165
Patel, YP, 1604(ab)
Pichler, BJ, 1574(ab)
Podoloff, DA, 12
Pozderac, RV, 1623(ab)
Pugliese, PV, 1568(ab), 1573(ab)

Q

Quang, E, 1564(ab)

R

Reilly, KG, 1566(ab)
Reissman, R, 1614(ab)
Rose, L, 1578(ab)
Rouse, E, 1562(ab)
Russell, JK, 1566(ab)

S

Sajdak, RA, 1563(ab)
Schmid, R, 1608(ab)
Schnitgen, MR, 1612(ab)
Schwaiger, M, 1565(ab), 1574(ab)
Seibyl, JP, 1615(ab)
Seino, K, 1557(ab)
Seldin, DW, 109
Semaan, HB, 1604(ab)
Shankovich, A, 1559(ab)
Sheetz, M, 1611(ab), 1612(ab)
Shen, S, 1580(ab)
Sinclair, H, 1628(ab)
Sperrazza, J, 1629(ab)
Spicer, KM, 1616(ab)
Spies, SM, 1552(ab)
Spieth, ME, 128, 1621(ab), 1622(ab), 1626(ab), 1627(ab)
Stabin, MG, 1624(ab)
Stratz, SL, 1627(ab)
Suarino, VM, 1627(ab)
Sumi, Y, 1570(ab)
Szulc, M, 1551(ab)

T

Tanaka, R, 1557(ab)
Tatsumi, M, 1577(ab)
Thomsen, G, 1610(ab)
Tomas, MB, 1568(ab), 1573(ab)
Topham, L, 21
Torok, F, 1611(ab), 1612(ab)
Torok, FS, 1614(ab)
Totah, D, 21
Toyama, H, 1555(ab)
Treves, ST, 1560(ab), 1613(ab)
Tronco, G, 1573(ab)
Tuinstra, NL, 1579(ab)
Turkington, T, 63(le), 175

U

Uffelman, W, 35, 61, 145, 206

V

Van der Wall, H, 1601(ab)
Van Eerd, JE, 1576(ab)
Van Gaal, W, 1601(ab)
Van Heertum, RL, 1556(ab)
Varzegar, R, 1602(ab)
Vilani, JW, 1629(ab), 1630(ab)
Vines, DC, 1555(ab)

W

Wahl, R, 1577(ab)
Wahl, RL, 1569(ab)
Wang, JK, 1571(ab)
Warner, J, 18
Warren, M, 1562(ab)
Waxman, AD, 1561(ab)
Weber, WA, 1565(ab), 1574(ab)
Wen, J, 1607(ab)
Wiggs, SD, 1564(ab)
Wilke, R, 21
Williams, RC, 123
Wilson, TE, 1613(ab)
Winter, A, 1565(ab)
Wiseman, GA, 1579(ab)
Witzig, TE, 1579(ab)
Woldenberg, LS, 1604(ab)
Wong, FJ, 1551(ab)
Wright, AA, 1553(ab)
Wu, LC, 1567(ab), 1571(ab)

X

Xiong, W, 1566(ab)

Y

Ye, X, 1625(ab)
Yeh, TS, 1567(ab)
Yu, CL, 1571(ab)
Yu, J, 1616(ab)

Z

Zajko, A, 1611(ab), 1612(ab)
Zakeri, F, 1602(ab)
Zander, A, 1605(ab)
Zea-Ponce, Y, 1556(ab)
Zheng, XM, 118, 123
Zhu, Z, 1556(ab)
Ziegler, SI, 1565(ab), 1574(ab)
Zubeldia, JM, 3

Subject Index—2002

Note: (ab) represents abstract

A

Adverse reactions, noncardiac, dipyridamole, in cardiac stress testing, 21
Alzheimer's disease, milameline treatment, detection of CBF changes after, SPECT, 118
Artifacts
arm positioning effects, rest/stress SPECT myocardial perfusion imaging, 150(ab)
contamination problems, sentinel node localization procedure, 18

B

Bexxar, techniques for using, Non-Hodgkin's lymphoma, 109
Blood-pool imaging
2D planar *versus* 2D SPECT, ejection fractions, 1626(ab)
gated
automated *versus* MUGA-C, 1628(ab)
right ventricular function and volume analysis, 1558(ab)
Bone scan, ^{99m}Tc MDP, penile implant on, 128
Book reviews
A Clinician's Guide to Nuclear Medicine, 31
Nuclear Medicine: Cardiology (Topic 5: Myocardial Perfusion Scintigraphy—Technical Aspects), 189
Nuclear Medicine: Cardiology (Topic 6: Myocardial Perfusion Scintigraphy—Clinical Aspects), 130
Breast, scintimammography, ^{99m}Tc MIBI SPECT, attenuation-free, 1578(ab)

C

Caffeine, serum levels after 24-hour abstention, implications for dipyridamole in myocardial imaging, 123
Cerebral blood flow, regional, Alzheimer patients after milameline treatment, 118
Cerebral SPECT
dopamine D2 receptor occupancy, antipsychotic drugs, 1556(ab)
quantitative, use of striatal phantom, evaluation of scatter correction, 1555(ab)
Cholelithiasis, CCK-3 infusion during hepatobiliary imaging, 1604(ab)
Chromosome aberration, workers in nuclear medicine centers in Iran, 1603(ab)
Cognitive activation, milameline treatment of Alzheimer patients, detection of CBF changes after, SPECT, 118
Coincidence imaging, dual-head-hybrid PET, measured transmission correction using, 1608(ab)
Consciousness, impairment of, ^{99m}Tc HMPAO SPECT use in, 1610(ab)
Cyclosporine, aerosol, lung deposition of, transplant recipients, 1614(ab)

D

Data acquisition, in PET, 39
Dipyridamole
adverse reactions to, stress/rest cardiac perfusion testing, 21
myocardial perfusion imaging, serum caffeine level implications on, 123
Dopamine transporters, ^{123}I altropane SPECT, test-retest variability, 1609(ab)
Dose calibrator, determination of settings, radionuclides exceeding potentiometer range, 1629(ab)
Dosimetry
radiation, measuring and minimizing the dose, technologists, 25
reproducibility of calculations, radioimmunoimaging, 1603(ab)
Downscatter, single acquisition studies, gated ^{99m}Tc tetrofosmin and FDG comparison, 175
Dual-isotope single acquisition studies, gated ^{99m}Tc tetrofosmin and FDG comparison, 175

E

Editor's page, 1, 37, 107, 151
Esophageal scintigraphy, transit and reflux, 1554(ab)
Expert systems, myocardial SPECT, interpretation and reporting of, 153

F

Fluorine-18 FDG
gated ^{99m}Tc tetrofosmin and, single-acquisition and separate acquisition protocols, 175
PET
benign entities mimicking malignancy, 1623(ab)
clinical applications in oncology, 3
CT fusing and, radiation oncology, 1563(ab)
detection of residual disease after chemotherapy in NSCLC, 1575(ab)
dosage of, body weight effects, 1565(ab)
injected dose based on body size, higher quality scans and, 1577(ab)
LS174T carcinoma and *E. coli* infection, rat, 1576(ab)
stabilizing of body temperature of small animals, 1574(ab)
standard uptake values, patient weight and residual dosage effects, 1622(ab)
Fusion imaging, new type of imaging, 201

G

Gamma camera, mobile, use in pediatrics, 1613(ab)
Gastroesophageal reflux (GER), scintigraphy, esophageal transit and, 1554(ab)

H

Hepatobiliary imaging, CCK-8 infusion during, diagnosed cholelithiasis, 1604(ab)
Hyperparathyroidism, improvement of diagnosis, dual-phase ^{99m}Tc sestamibi imaging and, 179

I

Image analysis, pinhole imaging, utility for foot and ankle, 1601(ab)
Image fusion
nuclear technique, location of anatomical abnormality, 1564(ab)
PET/CT display, optimizing visual interpretation of, 1571(ab)
phantom measurements, validation of tool, 1605(ab)
Image interpretation, myocardial SPECT, 153
Image management
display on WWW, 1566(ab)
Image reconstruction
fan-beam and variable-focal-length fan-beam SPECT, nonuniform attenuation, 1607(ab)
PET, data acquisition in, 39
Instrumentation
dose calibrator settings, radionuclides exceeding potentiometer range, 1629(ab)
intraoperative gamma probes, dead-time effects, 1606(ab)
PET, 63(le)
small solid-state digital gamma camera, use in pediatrics, 1613(ab)
Iodine-123, interruption of breast-feeding after, 1624(ab)
Iodine-125, interruption of breast feeding after, 1624(ab)
Iodine-131
outpatient therapy, thyroid cancer, 165
techniques for using, Non-Hodgkin's lymphoma, 109
Iodine-123 altropane, SPECT, test-retest variability, 1609(ab)

J

Joint Review Committee on Educational Programs in Nuclear Medicine (JRCNMT), 59, 134

L

Left ventricular ejection fraction, 2D planar *versus* 3D SPECT blood-pool imaging, 1626(ab)
Liver cancer
lung shunting in
planar and SPECT imaging for, 1611(ab)
variability of ^{99m}Tc MAA measurements, 1612(ab)
^{90}Y microsphere hepatopulmonary shunt estimation procedures, 1553
Lung
aerosol cyclosporine clearance, transplant recipients, 1614(ab)
shunting
in hepatic cancer, planar and SPECT imaging for, 1611(ab)
variability of ^{99m}Tc MAA measurements, 1612(ab)

ventilation-perfusion coregistration, comparison with planar imaging, 1561(ab)
Lung cancer, non-small cell, residual disease after, FDG PET in detection of, 1575(ab)
Lymphoma
Bexxar for treatment of, 109
reproducibility of dosimetric calculations, radioimmunoimaging, 1603(ab)
Lymphoscintigraphy
sentinel node, contamination problem with, 18
whole-body, using transmission scans, 12

M

Melanoma, whole-body lymphoscintigraphy, with transmission scans, 12
Message from the President, 2, 38, 108, 152
Multimodality imaging
combined PET/CT
optimizing visual interpretation of, 1571(ab)
quality control, 1569(ab)
Myocardial infarction, acute, after reperfusion, delayed ^{99m}Tc sestamibi and ^{123}I BMIPP images in, 1557(ab)
Myocardial perfusion imaging
dipyridamole, serum caffeine level implications on, 123
rest-stress
adverse reactions to dipyridamole, 21
arm positioning effects, 1560(ab)
one- and three-hour delays, comparison of activity, 1621(ab)
Myocardial SPECT
interpretation and reporting, 153
rest-stress, arm positioning effects, 1560(ab)

N

Neural networks, myocardial SPECT, interpretation and reporting of, 153
Non-Hodgkin's lymphoma (NHL)
Bexxar for treatment of, 109
Zevalin for, infusion symptoms, 1579(ab)
Nuclear cardiology, specialty examination, NMTCB, 53
Nuclear medicine
phantom measurements, validation of image fusion tool, 1605(ab)
studies, semi-automated example case file system for, 1572(ab)
training, integrated teaching laboratory for, 1630(ab)
Nuclear medicine technologists
analysis of salaries, 194
fusion imaging, 201
measuring and minimizing radiation dose, 25
scope of practice, 64
Nuclear Medicine Technologists Certification Board (NMTCB)
nuclear cardiology specialty examination, 53
report, 33, 57, 130, 190

O

Occupational dose, radiation, measuring and minimizing for technologists, 25
Oncology, ^{18}F FDG applications in, 3
Organ volume, exact estimation of, nuclear imaging procedures, 1568(ab)
Osteopenia, three sites in, 1627(ab)
Osteoporosis, three sites in, 1627(ab)
Ovarian cancer, intraperitoneal radioimmunotherapy, 1580(ab)

P

Parathyroid hyperplasia, dual-phase ^{99m}Tc sestamibi imaging, 179
Parathyroid imaging, dual-phase, improvement in diagnosis of hyperparathyroidism, 179
Pediatric patients, small solid state digital mobile camera, 1613(ab)
Penile implant, on bone scan imaging, 128
PET
after recombinant human thyrotropin injection, high-dose radioiodine therapy, 185
data acquisition in, 39
FDG
applications, in oncology, 3
injected dose based on body size, higher quality scans and, 1577(ab)
LS174T carcinoma and *E.coli* infection, rat, 1576(ab)
hybrid whole-body, acquisition process, 1573(ab)
introduction to instrumentation, 63(le)
stabilizing of body temperature, small animal imaging, 1574(ab)
tracer kinetic modeling in, web-based COM application, 1567(ab)
whole-body, body weight effects on count statistics, 1565(ab)
Pinhole imaging. *see also* SPECT
utility of, foot and ankle, 1606(ab)
Probe systems, intraoperative gamma probes, dead-time effects, 1606(ab)
Pulmonary embolism
early diagnosis and management, D-dimers and V/Q scan, 1562(ab)
imaging after introduction of pulmonary CT angiography, tertiary care center, 1615(ab)

Q

Quality control, clinical PET/CT, 1569(ab)

R

Radiation exposure
chromosome aberration, workers in nuclear medicine centers in Iran, 1602(ab)
protective radiation devices, evaluation of, 1553(ab)
Radiation oncology, fusing PET and CT in, 1563(ab)
Radiation safety, measuring and minimizing the dose, nuclear medicine technologists, 25
Radioimmunotherapy
Bexxar, treatment of Non-Hodgkin's lymphoma, 109
intraperitoneal, ovarian cancer, 1580(ab)
Zevalin, non-Hodgkin's lymphoma, infusion symptoms, 1579(ab)
Radioiodine therapy
^{131}I, thyroid cancer, 165
recombinant human thyrotropin in, thyroid cancer, 185
Radiopharmaceuticals, diagnostic, radiation protective devices, 1552(ab)
Right ventricular function, volume and, gated SPECT blood-pool imaging, 1558(ab)

S

Salary analysis, nuclear medicine technologists, 194
Scatter correction
evaluation with striatal phantom, quantitative brain SPECT, 1555(ab)
triple energy window, cross-talk ratio, SPECT, 1570(ab)
Schizophrenia, dopamine D2 receptor occupancy, antipsychotic drugs, ^{123}I IBZM SPECT, 1556(ab)
Sentinel node imaging, contamination problems with, 18
Serotonin transporters, bound ^{123}I ADAM in, rabbit brains, SPECT, 1625(ab)
SPECT
activation *versus* baseline, regional CBF changes in Alzheimer after milameline treatment, 118
dual-isotope imaging
location of anatomical abnormality, 1564(ab)
reducing cross-talk ratio, triple energy window scatter correction in, 1570(ab)
^{123}I ADAM, in serotonin transporters, rabbit brain, 1625(ab)
nonuniform attenuation, image reconstruction with, 1607(ab)

T

Technetium-99m HMPAO, SPECT, prolonged impaired consciousness and, 1610(ab)
Technetium-99m MDP, bone scan, penile implant on, 128
Technetium-99m MIBI
plastic syringe adsorption of, stability and, 1616(ab)
SPECT, attenuation-free, breast scintigraphy, 1578(ab)
Technetium-99m NOET, regional cardiac activity, comparison to ^{99m}Tc sestamibi, 1559(ab)
Technetium-99m sestamibi
cardiac perfusion testing, adverse reactions to dipyridamole, 21
delayed images, acute myocardial infarction after, reperfusion therapy, 1557(ab)
dual-phase, improvement in diagnosis of hyperparathyroidism, 179
Technetium-99m tetrofosmin
gated, FDG studies and, comparison, 175
plastic syringe adsorption of, stability and, 1616(ab)
Technologist news, 35, 61, 145, 205
Thallium-201
cardiac perfusion testing, adverse reactions to dipyridamole, 21
myocardial perfusion imaging, dipyridamole, serum caffeine level implications on, 123
Thyroid cancer
differentiated, value of recombinant human thyrotropin in, 185
^{131}I treatment, high-dose outpatient, 165
Thyrotropin, recombinant human, value in high-dose radioiodine therapy, 185

Tracer kinetic modeling
PET, Web-based COM application, 1567(ab)

Transmission tomography, lymphoscintigraphy using, 12

Treadmill stress testing, ambient exposure from minor spills, duct tape protection, 1551(ab)

V

Ventilation-perfusion imaging
after introduction of pulmonary CT angiography, tertiary care center, 1615(ab)
registration, lung, comparison with planar, 1561(ab)

Volume visualization, organ, nuclear imaging procedures, 1568(ab)

W

World Wide Web (WWW), diagnostic and nuclear medicine image display, 1566(ab)

Y

Yttrium-90, therapy evaluation, liver cancer, 1553(ab)

United States Postal Service

Statement of Ownership, Management, and Circulation

1. Publication Title	2. Publication Number	3. Filing Date
The Journal of Nuclear Medicine Technology	9 6 6 5 - 0 0	10/1/02
4. Issue Frequency	5. Number of Issues Published Annually	6. Annual Subscription Price
Quarterly	Four	$80 US; $85 Canada & Pan Am; $90 elsewhere

7. Complete Mailing Address of Known Office of Publication *(Not printer) (Street, city, county, state, and ZIP+4)*
1850 Samuel Morse Drive, Reston, VA 20190-5316
Contact Person: Becky Haines
Telephone: 703-708-9000 x1239

8. Complete Mailing Address of Headquarters or General Business Office of Publisher *(Not printer)*
1850 Samuel Morse Drive, Reston, VA 20190-5316

9. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor *(Do not leave blank)*
Publisher *(Name and complete mailing address)*
Society of Nuclear Medicine, Inc.
1850 Samuel Morse Drive, Reston, VA 20190-5316

Editor *(Name and complete mailing address)*
Beth Harkness, MS
1850 Samuel Morse Drive, Reston, VA 20190-5316

Managing Editor *(Name and complete mailing address)*
Becky Haines
1850 Samuel Morse Drive, Reston, VA 20190-5316

10. Owner *(Do not leave blank. If the publication is owned by a corporation, give the name and address of the corporation immediately followed by the names and addresses of all stockholders owning or holding 1 percent or more of the total amount of stock. If not owned by a corporation, give the names and addresses of the individual owners. If owned by a partnership or other unincorporated firm, give its name and address as well as those of each individual owner. If the publication is published by a nonprofit organization, give its name and address.)*

Full Name	Complete Mailing Address
Society of Nuclear Medicine, Inc.	1850 Samuel Morse Drive Reston, VA 20190

11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities. If none, check box → ☒ None

Full Name	Complete Mailing Address

12. Tax Status *(For completion by nonprofit organizations authorized to mail at nonprofit rates) (Check one)*
The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes:
☒ Has Not Changed During Preceding 12 Months
☐ Has Changed During Preceding 12 Months *(Publisher must submit explanation of change with this statement)*

PS Form **3526**, October 1999 *(See Instructions on Reverse)*

13. Publication Title: The Journal of Nuclear Medicine Technology		14. Issue Date for Circulation Data Below: September 2002	
15. Extent and Nature of Circulation		Average No. Copies Each Issue During Preceding 12 Months	No. Copies of Single Issue Published Nearest to Filing Date
a. Total Number of Copies *(Net press run)*		7,710	7,715
b. Paid and/or Requested Circulation	(1) Paid/Requested Outside-County Mail Subscriptions Stated on Form 3541. *(Include advertiser's proof and exchange copies)*	7,305	7,332
	(2) Paid In-County Subscriptions Stated on Form 3541 *(Include advertiser's proof and exchange copies)*	0	0
	(3) Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and Other Non-USPS Paid Distribution	0	0
	(4) Other Classes Mailed Through the USPS	0	0
c. Total Paid and/or Requested Circulation *(Sum of 15b. (1), (2),(3), and (4))*		7,305	7,332
d. Free Distribution by Mail (Samples, complimentary, and other free)	(1) Outside-County as Stated on Form 3541	86	86
	(2) In-County as Stated on Form 3541	0	0
	(3) Other Classes Mailed Through the USPS	0	0
e. Free Distribution Outside the Mail *(Carriers or other means)*		125	109
f. Total Free Distribution *(Sum of 15d. and 15e.)*		211	195
g. Total Distribution *(Sum of 15c. and 15f)*		7,516	7,527
h. Copies not Distributed		315	188
i. Total *(Sum of 15g. and h.)*		7,831	7,715
j. Percent Paid and/or Requested Circulation *(15c. divided by 15g. times 100)*		97%	97%

16. Publication of Statement of Ownership
☒ Publication required. Will be printed in the December 2002 issue of this publication. ☐ Publication not required.

17. Signature and Title of Editor, Publisher, Business Manager, or Owner: G. Rebecca Haines, Director of Publications — Date: 10/2/02

I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information requested on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including civil penalties).

Instructions to Publishers

1. Complete and file one copy of this form with your postmaster annually on or before October 1. Keep a copy of the completed form for your records.
2. In cases where the stockholder or security holder is a trustee, include in items 10 and 11 the name of the person or corporation for whom the trustee is acting. Also include the names and addresses of individuals who are stockholders who own or hold 1 percent or more of the total amount of bonds, mortgages, or other securities of the publishing corporation. In item 11, if none, check the box. Use blank sheets if more space is required.
3. Be sure to furnish all circulation information called for in item 15. Free circulation must be shown in items 15d, e, and f.
4. Item 15h., Copies not Distributed, must include (1) newsstand copies originally stated on Form 3541, and returned to the publisher, (2) estimated returns from news agents, and (3), copies for office use, leftovers, spoiled, and all other copies not distributed.
5. If the publication had Periodicals authorization as a general or requester publication, this Statement of Ownership, Management, and Circulation must be published; it must be printed in any issue in October or, if the publication is not published during October, the first issue printed after October.
6. In item 16, indicate the date of the issue in which this Statement of Ownership will be published.
7. Item 17 must be signed.

Failure to file or publish a statement of ownership may lead to suspension of Periodicals authorization.

PS Form **3526**, October 1999 *(Reverse)*